Vaccines and therapeutics for immunocompromised patients with COVID-19.

Journal: EClinicalMedicine

Volume: 59

Issue: 

Year of Publication: 

Affiliated Institutions:  Johns Hopkins University School of Medicine, Baltimore, MD, USA. Médecins Sans Frontières, Rio de Janeiro, Brazil. Center for Sustainable Development, Columbia University, New York, NY, USA. Koc University Research Center for Infectious Diseases, Istanbul, Turkey. College of Medicine, King Saud University, Riyadh, Saudi Arabia. Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USA. Christian Medical College, Vellore, India. International Vaccine Institute, Seoul, South Korea. University of Houston Tilman J. Fertitta Family College of Medicine, Houston, TX, USA. London School of Hygiene & Tropical Medicine, London, UK. ISGlobal, Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, Spain. University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, USA. Center for Vaccine Development, Bamako, Mali. Center for Global Development, Washington, DC, USA.

Abstract summary 

The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients' immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches.

Authors & Co-authors:  Shoham Shmuel S Batista Carolina C Ben Amor Yanis Y Ergonul Onder O Hassanain Mazen M Hotez Peter P Kang Gagandeep G Kim Jerome H JH Lall Bhavna B Larson Heidi J HJ Naniche Denise D Sheahan Timothy T Strub-Wourgaft Nathalie N Sow Samba O SO Wilder-Smith Annelies A Yadav Prashant P Bottazzi Maria Elena ME

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Harpaz R., Dahl R.M., Dooling K.L. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547–2548.
Authors :  18
Identifiers
Doi : 101965
SSN : 2589-5370
Study Population
Male,Female
Mesh Terms
Other Terms
COVID-19;Immunocompromised;Malignancy;SARS-CoV-2;Transplantation
Study Design
Study Approach
Country of Study
Mali
Publication Country
England